Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc's stock showed a significant rebound with a nearly 500% increase following the full HARMONi-2 dataset disclosure, indicating strong market confidence in its tumor infiltrating lymphocyte (TIL) therapies. The company's unique CoStAR platform for genetically engineered TIL therapies opens pathways to treat various solid tumors, enhancing its competitive edge within the biopharmaceutical landscape. Furthermore, a discounted cash flow analysis estimated the firm's value at approximately $884 million, reflecting the potential for substantial growth driven by ongoing research and favorable developments in the industry.

Bears say

Instil Bio reported a net loss of $1.82 for the fourth quarter of 2024, contributing to a projected full-year net loss of $11.51 per share for 2025, a significant increase from the previously estimated loss of $3.65 per share. Key risks impacting the company's outlook include potential delays in the clinical development of its therapies, particularly related to the performance of candidate AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as well as the possibility of future dilution. These factors collectively cast a negative outlook on Instil Bio’s financial stability and performance trajectory.

Instil Bio (TIL) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Buy based on their latest research and market trends.

According to 5 analysts, Instil Bio (TIL) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.